Results 31 to 40 of about 4,256 (179)

Bilirubin Safeguards Cardiorenal and Metabolic Diseases: a Protective Role in Health [PDF]

Current Hypertension Reports, 2019
To discuss recent advances indicating that bilirubin safeguards against cardiorenal and metabolic diseases.Several investigations from human patient populations and experimental animal models have shown that bilirubin improves cardiorenal and metabolic dysfunction.
Terry D, Hinds, David E, Stec
openaire   +2 more sources

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering

BMJ Open Diabetes Research & Care, 2023
IntroductionRelationships between glycemic-lowering effects of sodium glucose co-transporter 2 inhibitors and impact on kidney and cardiovascular outcomes are uncertain.Research design and methodsWe analyzed 4395 individuals with prebaseline and postbaseline hemoglobin A1c (HbA1c) randomized to canagliflozin (n=2193) or placebo (n=2202) in The ...
Charytan, DM, Mahaffey, KW, Jardine, MJ, Cannon, CP, Neal, B, Lambers Heerspink, HJ, Agarwal, R, Bakris, GL, De Zeeuw, D, Levin, A, Pollock, C, Zhang, H, Zinman, B, Rosenthal, N, Perkovic, V, Di Tanna, GL, Yu, J, Rogers, K, Arnott, C, Wheeler, DC   +19 more
openaire   +5 more sources

Omega-3 fatty acids ameliorate doxorubicin-induced cardiorenal toxicity: In-vivo regulation of oxidative stress, apoptosis and renal Nox4, and in-vitro preservation of the cytotoxic efficacy.

PLoS ONE, 2020
This study examines the protective effects of omega-3 fatty acids (OMG), a frequently used nutritional therapy in cancer patients, against doxorubicin (DOX)-induced acute cardiorenal toxicity in rats, and evaluates the cytotoxic activity of DOX when used
Dalia Saleh, Marawan Abdelbaset, Azza Hassan, Ola Sharaf, Sawsan Mahmoud, Rehab Hegazy   +5 more
doaj   +1 more source

Reframing SGLT2 inhibition as systematic metabolic stress modulation across the cardiovascular-renal-metabolic axis [PDF]

Exploration of Cardiology
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) were originally developed as glucose-lowering therapies for type 2 diabetes mellitus. However, robust clinical evidence has demonstrated substantial cardiovascular and renal protective effects that ...
Nabil Tariq, Afra Wasama Islam, Preshita Dhadke, Tabish Patel, Mehreen Rasheed Muhammad, Mohammed Aawesh, Subia Rasheed Muhammad, Burhan Tahir   +7 more
doaj   +1 more source

N-Acetylcysteine–Enhanced Contrast Provides Cardiorenal Protection

JACC: Cardiovascular Interventions, 2009
We sought to evaluate the cardiac and renal effects of an N-acetylcysteine (NAC)-enhanced intracoronary radiographic contrast agent.Recent studies suggest that high-dose NAC provides better protection from contrast-induced nephropathy, and the antioxidant properties of NAC may also provide cardiac protection.
Meyer, Markus, LeWinter, Martin M., Bell, Stephen P., Chen, Zengyi, Selby, Donald E., Singla, Dinender K., Dauerman, Harold L.   +6 more
openaire   +2 more sources

Efficacy and safety of empagliflozin in patients over 65 with type 2 diabetes mellitus complicating cardiorenal syndromes type II and IV [PDF]

Journal of Medical Biochemistry
Background: Cardiorenal syndrome (CRS) is a complex clinical condition that leads to deterioration in both cardiac and renal functions. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is a novel anti-diabetic drug that also improves ...
Cao Mugen, Lin Qiuyan, Lin Liling, Zhang Wenjie, Zhang Lifeng   +4 more
doaj   +1 more source

Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future

Biomedicines
Cardiovascular disease (CVD) and kidney disease are the main causes of morbidity and mortality in type 2 diabetes mellitus (T2DM). Globally, the incidence of T2DM continues to rise. A substantial increase in the burden of CVD and renal disease, alongside
Ying Jie Chee, Rinkoo Dalan
doaj   +1 more source

Bioactive Peptides from Ruditapes philippinarum Attenuate Hypertension and Cardiorenal Damage in Deoxycorticosterone Acetate–Salt Hypertensive Rats

Molecules, 2023
Hypertension is a common disease that affects human health and can lead to damage to the heart, kidneys, and other important organs. In this study, we investigated the regulatory effects of bioactive peptides derived from Ruditapes philippinarum (RPP) on
Zonghui Sun, Weixia Wang, Jinli Liu, Shengcan Zou, Dongli Yin, Chenghan Lyu, Jia Yu, Yuxi Wei   +7 more
doaj   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Diabetic kidney disease: from pathogenesis to multimodal therapy–current evidence and future directions

Frontiers in Medicine
Diabetic kidney disease (DKD) has emerged as the leading cause of chronic kidney disease (CKD) worldwide, surpassing primary glomerular disorders in prevalence.
Hui Zhang, Keding Wang, Hairui Zhao, Bowen Qin, Xiaojing Cai, Manyi Wu, Junhua Li, Junhua Li, Jielian Wang   +8 more
doaj   +1 more source